Pharmaceutical Giants Bet Big on Blockbuster Drugs, Relying on Hefty Balance Sheets In a high-stakes game of medical innovation, pharmaceutical companies are rolling the dice, investing billions of dollars in the development of potential blockbuster drugs. With massive balance sheets as their safety net, these industry giants can afford to take risks on unproven treatments, hoping to strike gold with a life-changing medication. As the cost of research and development continues to soar, companies are relying on their financial muscle to stay ahead of the competition and bring new treatments to market. But with the failure rate for new drugs running high, can these massive bets pay off, or will they leave investors empty-handed?
Sheer mass helps when enlarged balance sheets allow for bigger bets on potential blockbuster drugs
